1-Greenhill LL, Hechtman LI. Attention-Deficit/Hyperactivity Disorder. In: Sadock BJ, Sadock VA, Ruiz P. Comprehensive Text Book of Psychiatry. 9th ed. Philadelphia: Lippincott, Williams & Wilkins; 2009: 3560-72.
2-Sadock BG, Sadock VA . Kaplan and Sadock's Synopsis of psychiatry, behavioral clinical psychiatry.10th ed. Philadelphia (PA): Lippincott, Williams & Wilkins; 2007: 1044,1206-1217.
3-Hakim shooshtary M, Chimeh N, Najafi M, "et al". The prevalence of attention deficit Hyperactivity disorder in Iran: A systematic review. Iran J Psychiatry 2010; 5: 88-92.
4-Tashakori A, Afkandeh R. prevalence of ADHD symptoms among male preschoolers based on different informants in Ahvaz city in Iran. ISRN Pediatrics 2011july; 2011: 1-4.
5-Wilens TE, Biederman J. ADHD across the life span. Annual reviews connect of medicine 2002 Feb; 53: 113-131.
6-Biederman J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 2005; 57:1215–1220.
7-Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, "et al". Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005; 57: 1442–1451.
8-Carrey N, MacMaster FP, Fogel J, Sparkes S, Waschbusch D, Sullivan S, "et al". Metabolite changes resulting from treatment in children with ADHD: A 1H-MRS study. Clin Neuropharmacol 2003July-agust; 26(4): 218–221.
9-Riahi F, Tashakori A, Izadi-Mazidi S, Salehi-Veisi M. Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit/ hyperactivity disorder with comorbid anxiety disorders. Iran J Psychiatry 2013; 8(4): 195-200.
10-Russell VA. Increased AMPA receptor function in slices containing the prefrontal cortex of spontaneously hypertensive rats. Metab Brain Dis 2001 Dec; 16(3,4): 143–149.
11-Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH,: AD2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 2002 Sep; 35(6): 1111-1122.
12-Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST Study (Benefit andefficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–146.
13-Forest Laboratories: Data on file. New York: Forest Laboratories, Inc; 2005.
14-Findling RL,McNamark Nk. A pilot evaluation of the safety ,tolerability,pharmacokinetics and effectiveness in pediatric patients with attention-deficit/hyperactivity disorder combined type. J child adolesc psychopharmacol 2007; 17(1): 19-33.
15-Erickson F. A retrospective study of memantine in children and adolescents with PDD, psychopharmacology 2007; 191: 141-147.
16-Mohammadzadeh S, Mohammadi MR, Akhondzadeh S. comparison of memantine and ritalin in the treatment of children with ADHD. Proceeding of the Iranian 6th International congress of child and adolescent psychiatry; 2013 Sep 17-19; Iran: Tabriz; 2013. P. 171.
17-Weiss M, Weiss G. Attention Deficit- Hyperactivity Disorder. In: Martin A, Volkmar FR. Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook. 3rd ed. Philadelphia (PA): Lippincott, Williams & Wilkins; 2002, P: 645-51.
18-Brock SE, Clinton A. Diagnosis of attention deficit/ hyperactivity disorder (AD/HD) in childhood: A review of the literature. J child Dev 2007; (12):73-91.
20-Jann MW, Small GW. Cholinesterase inhibitors. In: Sadock BJ, Sadock VA, Ruiz P. Comprehensive Text Book of Psychiatry. 9th ed. Philadelphia: Lippincott, Williams & Wilkins; 2009: 3096-7.
)